• 
  Florentin Pastor, Emilie Charles, Lucid Belmudes, Hélène Chabrolles, Marion Cescato, et al.. Deciphering the phospho-signature induced by hepatitis B virus in primary human hepatocytes. Frontiers in Microbiology, 2024, 15, pp.1415449. ⟨10.3389/fmicb.2024.1415449⟩. ⟨hal-04583052⟩
• 
  Andrea Brancale, Kara Carter, Leen Delang, Jerome Deval, David Durantel, et al.. Meeting report: 34th international conference on antiviral research. Antiviral Chemistry and Chemotherapy, 2022, 30, pp.204020662211308. ⟨10.1177/20402066221130853⟩. ⟨hal-04121353⟩
• 
  Jil Schrader, Thomas Burkard, Yannick Brüggemann, André Gömer, Toni Meister, et al.. EGF receptor modulates HEV entry in human hepatocytes. Hepatology, 2023, 77 (6), pp.2104-2117. ⟨10.1097/HEP.0000000000000308⟩. ⟨hal-04120975⟩
• 
  David Durantel. Therapies against chronic hepatitis B infections: The times they are a-changin’, but the changing is slow!. Antiviral Research, 2023, 210, pp.105515. ⟨10.1016/j.antiviral.2022.105515⟩. ⟨hal-04120908⟩
• 
  Anne-Flore Legrand, Julie Lucifora, Benoît Lacombe, Camille Ménard, Maud Michelet, et al.. Farnesoid X receptor alpha ligands inhibit HDV in vitro replication and virion infectivity. Hepatology Communications, 2023, 7 (5), pp.e0078. ⟨10.1097/HC9.0000000000000078⟩. ⟨hal-04072355⟩
• 
  Knud Esser, Xiaoming Cheng, Jochen Wettengel, Julie Lucifora, Lea Hansen-Palmus, et al.. Hepatitis B virus targets lipid transport pathways to infect hepatocytes. Cellular and Molecular Gastroenterology and Hepatology, In press, ⟨10.1016/j.jcmgh.2023.03.011⟩. ⟨hal-04069375⟩
• 
  Julie Lucifora, Eloi Verrier, Thomas F. Baumert. Inhibiting cell-to-cell transmission to reach HDV cure: The importance of IFN-α.. Journal of hepatology, 2022, 77 (4), pp.903-905. ⟨10.1016/j.jhep.2022.07.015⟩. ⟨hal-04042051⟩
• 
  Lena Allweiss, Barbara Testoni, Mei Yu, Julie Lucifora, Chunkyu Ko, et al.. Quantification of the Hepatitis B Virus cccDNA: Evidence-based guidelines for 2 monitoring the key obstacle of HBV cure 3 Short Title: cccDNA quantification harmonization 4 5. Gut, 2023, pp.gutjnl-2022-328380. ⟨10.1136/gutjnl-2022-328380⟩. ⟨hal-03992742⟩
• 
  Julie Lucifora, Dulce Alfaiate, Caroline Pons, Maud Michelet, Ricardo Ramirez, et al.. Hepatitis D virus interferes with hepatitis B virus RNA production via interferon-dependent and -independent mechanisms. Journal of Hepatology, In press, ⟨10.1016/j.jhep.2023.01.005⟩. ⟨hal-03992721⟩
• 
  Myriam Lamrayah, Fanny Charriaud, Manon Desmares, Céline Coiffier, Simon Megy, et al.. Induction of a strong and long-lasting neutralizing immune response by dPreS1-TLR2 agonist nanovaccine against hepatitis B virus. Antiviral Research, 2023, 209, pp.105483. ⟨10.1016/j.antiviral.2022.105483⟩. ⟨hal-03923266⟩
• 
  Charlotte Bach, Julie Lucifora, Marion Delphin, Laura Heydmann, Margaux Heuschkel, et al.. A stable hepatitis D virus-producing cell line for host target and drug discovery. Antiviral Research, 2023, 209, pp.105477. ⟨10.1016/j.antiviral.2022.105477⟩. ⟨hal-03883116⟩
• 
  Manon Desmares, Marion Delphin, Brieux Chardès, Caroline Pons, Juliette Riedinger, et al.. Insights on the antiviral mechanisms of action of the TLR1/2 agonist Pam3CSK4 in hepatitis B virus (HBV)-infected hepatocytes. Antiviral Research, 2022, 206, pp.105386. ⟨10.1016/j.antiviral.2022.105386⟩. ⟨hal-03869860⟩
• 
  Mathieu Claviere, Aude Lavedrine, Guénaëlle Lamiral, Mariette Bonnet, Pauline Verlhac, et al.. Measles virus-imposed remodeling of the autophagy machinery determines the outcome of bacterial coinfection. Autophagy, 2022, pp.1 - 15. ⟨10.1080/15548627.2022.2107309⟩. ⟨hal-03845891⟩
• 
  Eloi R Verrier, Anna Salvetti, Caroline Pons, Maud Michelet, Michel Rivoire, et al.. Loss of hepatitis D virus infectivity upon farnesyl transferase inhibitor treatment associates with increasing RNA editing rates revealed by a new RT-ddPCR method. Antiviral Research, 2022, 198, pp.105250. ⟨10.1016/j.antiviral.2022.105250⟩. ⟨hal-03540952⟩
• 
  Maud Michelet, Dulce Alfaiate, Brieux Chardès, Caroline Pons, Suzanne Faure-Dupuy, et al.. Inducers of NF-κB pathways impair hepatitis delta virus replication and strongly decrease progeny infectivity in vitro. JHEP Reports Innovation in Hepatology, 2021, pp.100415. ⟨10.1016/j.jhepr.2021.100415⟩. ⟨hal-03520759⟩

17

6